Drug Profile

Sepranolone - Asarina Pharma

Alternative Names: Isoallopregnanolone; UC-1010

Latest Information Update: 21 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Umecrine Mood
Developer Asarina Pharma
Class Antidepressants; Antimigraines
Mechanism of Action GABA A receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Gilles de la Tourette's syndrome; Menstrual migraine; Premenstrual dysphoric disorder

Most Recent Events

12 May 2025 Relmada Therapeutics plans a meeting with the US FDA in 2025
12 May 2025 Efficacy data from a phase-II clinical trials in Gilles de la Tourette's syndrome released by Relmada Therapeutics
12 May 2025 Relmada Therapeutics plans a phase II trial for Gilles de la Tourette's syndrome (SC) in the first half of 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com